Susanne Somerville is the CEO of Chronicled, founded in 2014 with the hopes of building the ultimate enterprise blockchain platform. And more recently in 2017 she founded the Mediledger Network, one of the largest and most active healthcare/blockchain consortiums. Current working group members and partners include Genentech, Gilead, Bayer, Pfizer, PWC, SAP, Deloitte, IQVIA, GS1, Walmart and more. Susanne is trailblazing a path for pharma companies to use blockchain tech in a way that will improve their supply chain operations and revenue management processes. https://www.chronicled.com/ https://www.mediledger.com/ Show Notes •Introduction of Susanne's background •Journey from ChemE to Pharma supply chain to blockchain •Origins of Chronicled and Mediledger - value proposition, problem statement •How is COVID19 impacting healthcare supply chains? •Most challenging Supply Chain problems fit for DLT - data entry, track and tracing, temperature monitoring, fraud, counterfeits •What responsibilities does Chronicled have as the custodian of the MediLedger network? •Industry Standards – GS1 and HIBCC (Health Industry Business Communications Council) database •Customer mapping process and how different trading partners can align interests •Does Mediledger need blockchain? Why? •“It’s like putting your own private embassy behind your trading partners firewall” on the benefits of blockchain for multi-party data exchange •Chronicled Products - Product Verification / Contracts and Chargebacks •Network stakeholders - Healthcare providers, GPOs (Group purchasing organization), Manufacturers, distributors •Technical specifications (architecture) of Chronicled network •Permisssioned Blockchain protocol – Substrate/Parity Tech Stack •Data storage •Node participation and governance •Libp2p messaging •Smart contracts •FDA DSCSA pilot experience and learnings from regulators •Managing between data transparency and privacy •Chronicled team and culture around privacy and security •Industry Partners and concept traction - existing partners and pilot projects •Can you describe the competitive landscape and any direct competitors to your business? •Platform/Ecosystem roadmap 2020 and beyond •Favorite book – Midnight’s Children by Salman Rushdie •What do you believe in that most people would disagree with? •Who's your favorite US president of all time? •How are you handling with the physical distancing measures? •Final takeaways News Corner The COVID19 pandemic has highlighted how Genetic data may reveal susceptibility to certain diseases. On June 8, 23andme announced it has been conducted research studies to determine if blood type is associated with lower risk of infections or symptoms. In a person’s DNA, a Thymine base on their ABO gene determines if that person has blood type O. Early results suggest Individuals with O blood type are between 9-18% percent less likely than individuals with other blood types to have tested positive for COVID-19. This research study is continuing to grow and people are beginning to reconsider the role of genetic data in our digital world. https://blog.23andme.com/23andme-research/23andme-finds-evidence-that-blood-type-plays-a-role-in-covid-19/ Remember, the Health Unchained podcast is for informational and entertainment purposes only and we are not providing any sort of legal, financial, or medical advice. Please do your own research and due diligence before making any important decisions related to these matters. Special thanks to Bert Miller and Christiane Wirrig who both have newsletters covering the industry. https://bert.substack.com/ https://bluesteens.substack.com/ Health Unchained Links Website: https://healthunchained.org Telegram: t.me/healthunchained Twitter: twitter.com/Healthunchaind
